The bcl-2 family of genes encodes proteins that influence apoptosis. In the present immunohistochemical study, the topographic distribution of bcl-2 protein was examined in healthy feline fetal, neonatal, and adult tissues, a feline renal cell line, and feline tumors obtained from a veterinary hospital. The topographic distribution of bcl-2 in healthy tissues was similar to that described in human tissues. In lymphoid tissues, follicular mantle cells strongly expressed bcl-2. In complex and differentiating epithelium, bcl-2 expression was detected in stem cell and proliferation zones. Bcl-2 expression was also detected in lower crypts of the intestine and in skin basal layers. The feline Crandell kidney cells expressed bcl-2 diffusely throughout the cytoplasm. Of 180 tumors examined, bcl-2 was expressed almost uniformly in cutaneous basal cell tumors, thyroid adenomas, and mammary carcinomas and in 50% of the lymphomas examined. Bcl-2 may play a role in blocking apoptotic cell death in a broad range of normal feline tissues, whereas dysregulated bcl-2 may extend the life of certain tumors or render certain tumors resistant to therapy because most chemotherapeutic and radiotherapeutic agents eliminate tumor cells by triggering apoptosis.
Apoptosis is an essential and highly conserved mode of cell death that is important for normal development, host defense, and suppression of oncogenesis. 1 The bcl-2 family of genes encodes proteins that influence apoptosis or programmed cell death in fetal and adult tissues. Bcl-2 is the acronym for the B-cell lymphoma/leukemia-2 gene. This gene was first discovered because of its involvement in human B-cell malignancies, where t(14;18) chromosomal translocations activate the gene in follicular non-Hodgkin's Bcell lymphomas. 19 The translocation is associated with an increase in the expression of bcl-2 protein, thought to be due to the presence of enhancers in the immunoglobulin heavy chain gene. 5 Bcl-2 is constitutively expressed at low levels in both hematopoietic and nonhematopoietic tissues throughout the body. High levels of protein occur in nearly one-half of human tumors, suggesting that dysregulation of programmed cell death as a result of changes in expression of bcl-2 represents an important step in carcinogenesis. 19 Aside from human follicular lymphoma containing chromosomal translocations, bcl-2 is not grossly altered in solid tumors and most leukemias, and the mechanism(s) responsible for high levels of gene expression are largely unknown. 19 In health, bcl-2 expression is restricted to mature tissues that are characterized by programmed cell death. Within these tissues, bcl-2 expression is often topographically restricted to long-lived or proliferating cell zones. For example, in lymphoid germinal centers, the follicular mantle, which contains longlived recirculating B cells, possesses abundant bcl-2. Bcl-2 is also expressed in the surviving T cells in the thymic medulla. 13 Nonlymphoid tissues that express bcl-2 include those characterized by apoptosis: glandular epithelium in which growth hormones or growth factors regulate hyperplasia and involution, complex differentiating epithelium such as skin and intestine characterized by long-lived stem cells, and long-lived postmitotic cells such as neurons. 8, 14 The function of bcl-2 protein to inhibit apoptosis may confer longevity to progenitor and effector cells in these tissues in health, but it may also contribute to neoplastic cell growth by prolonging cell survival. Further, because most chemotherapeutic and radiotherapeutic agents eliminate tumor cells by triggering apoptosis, bcl-2 expression may render tumor cells resistant to therapy.
In the present immunohistochemical study, the topographic distribution of bcl-2 expression was examined in normal (healthy) feline embryonic, neonatal, and adult tissues and in a feline renal cell line. Bcl-2 expression was then examined in a variety of feline tumors encountered in a veterinary clinical setting.
Materials and Methods

Tissues
Tissues were collected at the time of euthanasia from a healthy 6-month-old female cat, a healthy 12-month-old female cat, second-trimester fetuses collected at the time of elective ovariohysterectomy, and healthy neonatal kittens less than 1 hour old. Representative samples of tissues were fixed in 10% phosphate-buffered formalin for 24 hours and routinely embedded in paraffin. Feline tumor tissues (180 specimens) were obtained from the pathology archives of the University of California Veterinary Medical Teaching Hospital and represented biopsy, but not necropsy, specimens. The tumors included carcinoma in situ, basal and squamous cell carcinoma of the skin, adenomas and carcinomas derived from the ceruminous glands of the ear canal, and carcinomas from the mammary gland, oral cavity, tonsils, nasal cavity, urinary bladder, gastrointestinal tract, and lung. Additional tumors examined included T-and B-cell lymphoma, meningioma, fibrosarcoma, thymoma, and thyroid adenoma.
The Crandall feline kidney cell line was obtained from the American Type Culture Collection (Bethesda, MD). Cells were maintained in log-phase monolayer culture in Iscove's medium supplemented with 10% fetal bovine serum and 2 mM glutamine. Cultures were maintained at 37 C in 94% air with 6% CO 2 in a humidified incubator. For immunohistochemistry, cells were detached with 0.05% trypsin and 0.53 mM ethylenediaminetetraacetic acid, adjusted to 150,000 cells/ml, loaded into chamber slides, incubated overnight, and fixed in 4% formalin in phosphate-buffered saline (PBS).
Immunohistochemistry
Bcl-2 expression was detected using an avidin-biotin staining procedure with diaminobenzidene-peroxidase and a commercial monoclonal bcl-2 antibody (BCL2, Novocastra Laboratories, Newcastle on Tine, UK). Five-micrometer sections were deparaffinized in xylene and 100% ethanol. Endogenous peroxidase was blocked by H 2 O 2 /3% methanol for 20 minutes. Sections were immersed for 2 minutes in 95% ethanol, 2 minutes in 75% ethanol, and 5 minutes in tap water. Microwave heating (high) was done in citrate buffer for two 2.4-minute cycles, and the sections allowed to cool for 5 minutes. Sections were rinsed twice for 5 minutes each time in PBS. Normal horse serum (10%) was applied to the sections for 20 minutes. The primary antibody to bcl-2 diluted 1 : 80 was applied to sections overnight at 4 C. The sections were rinsed twice with PBS for 5 minutes each time, and the secondary antibody (biotinylated horse anti-mouse, Vector Labs, Burlingame, CA) diluted 1 : 800 was applied at room temperature for 60 minutes. After rinsing twice in PBS for 5 minutes each time, avidin-biotin complex (ABC Elite, Vector Labs) at 1 : 50 dilution was applied for 30 minutes, followed by two 5-minute PBS rinses. After rinsing, diaminobenzidene-peroxidase (ScyTek Labs, Logan, UT) was applied for 3-5 minutes to achieve a permanent (brown) color change in the reactive cells. The sections were immersed in tap water for 5 minutes and stained with hematoxylin-Mayers for 30 seconds. The sections were dehydrated, cleared, and coverslipped. Duplicate sections subjected to all phases of staining except the primary antibody served as negative controls. Positive controls consisted of paraffin-embedded sections of previously tested formalin-fixed tissues, including normal feline and human small intestine. Sections were examined with a light microscope. The results were based on the percentage of positive cells; Ն10% immunoreactive cells was considered positive.
Detection of B and T lymphocytes in feline lymphoma specimens was done on formalin-fixed, paraffin-embedded tissue sections using similar immunohistochemical methods. Thin sections (5 m) were immunostained with primary antibody, biotinylated secondary antibody, streptavidin-peroxidase reagent, and 3Јamino-9-ethylcarbazol (Zymed Laboratories, South San Francisco, CA) as chromagen. Primary antibodies used included B220 (anti-CD45 or leukocyte common antigen; Dako Corp., Carpinteria, CA), anti-CD3 for T cells (rabbit anti-human CD3 T-cell polyclonal antibody; Dako Corp.) or monoclonal rat CD3 antibody (Vector Labs), HM57 (Dako Corp.) for detection of CD79a (B-cell receptor), and FR3.9F2 (provided by Dr. P. F. Moore, University of California, Davis, CA) for detection of macrophages.
Results
Healthy tissues
Adult tissues. Immunohistochemical staining revealed topographic distribution of bcl-2 in adult tissues analogous to that described in human tissues ( Table  1 ). 8 In surface epithelia, there was consistent staining of basal layers of mucous membranes, skin, and skin adnexae ( Fig. 1 ). Cells with progressive differentiation from the basal epithelium did not express bcl-2. In the tonsil, the basal epithelial cells expressed bcl-2, and scattered lymphocytes were reactive. In the tongue, basal cells were strongly positive. In the esophagus, the basilar epithelium was diffusely reactive. In stomach, there were focally reactive cells in squamous epithelium. In the small intestine (duodenum, jejunum, ileum), there was strong reactivity in the basal villous epithelial cells ( Fig. 2) , with similar reactivity in the colonic crypts and a gradient of decreasing intensity of staining along the crypt axis. Diffuse cytoplasmic reactivity was observed in the lower half of crypts in small and large intestine. There was strong reactivity of lymphoid cells in the intestinal submucosa and individual cells scattered throughout the lamina propria. Basal cells of rectal mucosa were reactive. Pancreatic islet cells were immunoreactive. In the spleen, there was strong reactivity within B-cell follicles. Strongly immunoreactive cells were present within the mature mantle or marginal zone, whereas cells within the germinal center were negative for bcl-2. Individual immunoreactive cells were scattered throughout the perifollicular and T-cell zones. The germinal centers within lymph nodes had similar distribution of immunoreactive cells, with strong staining of the mantle zone Feline bcl-2 and interfollicular cells ( Fig. 3 ). Cortical lymphocytes of the thymus were immunoreactive.
Follicular epithelium of the thyroid gland showed heterogenous expression of bcl-2, ranging from 0 to 100% (mean ϭ 33%) of follicle cells in 10 different specimens from 10 different cats ( Fig. 4 ). Renal distal convoluted tubules expressed bcl-2. In the adrenal gland, there was diffuse faint staining throughout the cortex, but the capsule and medulla were negative. Most components of the urinary bladder were nonreactive, although bcl-2 expression was observed in endothelium of blood vessels in the submucosae. Bronchial and bronchiolar epithelium expressed bcl-2, but the alveolar ducts were nonreactive. Glial cells of the cerebral cortex and cerebellum showed only scattered weak immunoreactivity. There was no immunoreactivity in peripheral nerve. There were focal immunoreactive cells in the adrenal cortex. In the eye, the corneal epithelial basal cells, corneal endothelium, and lens capsule epithelium were bcl-2 reactive. Liver, exocrine pancreas, skeletal muscle, and cardiac muscle were negative.
Neonatal tissues. In the neonatal cat, bcl-2 expression was present in basal layers of epidermis and follicular epithelium. Some stellate or spindle-shaped stromal connective tissue cells of the dermis were also immunoreactive. Brown fat identified in skin and other tissue sites expressed bcl-2. The basal epithelium of tongue, esophagus, and trachea was immunoreactive. In the small intestine, bcl-2 was detected in basal crypt cells, Brunner's glands, ganglion cells, gut-associated lymphoid tissue, and immature fat. Basal epithelium of rectum was bcl-2 reactive, but basal cells of the gastric mucosa were nonreactive. In the eye, corneal and conjunctival epithelium and uveal tract expressed bcl-2. The thymus showed diffuse expression of bcl-2 in medullary lymphoid cells and scattered reactivity in lymphoid cells throughout the cortex (Fig. 5 ). The uterus stained positively for bcl-2 throughout all layers. The deep layer of the myometrium had strong expression. There were scattered immunoreactive lymphoid cells in spleen. In kidney, bcl-2 was expressed in renal tubules and in peripheral cells of glomeruli. Adrenal cortex was weakly immunoreactive, with greatest staining intensity in the zonas fasciculata and reticularis; the adrenal medulla was nonreactive. The cerebral cortex of the brain contained immunoreactive cells in the external and lutiform layers (Fig. 6 ). Myeloid precursors in bone marrow expressed bcl-2. Osteocytes in the lacunae of cranium were reactive, as were chondrocytes, but chondrocytes of ear canal were nonreactive. Lung, urinary bladder, heart, and liver were nonreactive.
Fetal tissues and placenta. Feline second-trimester placenta showed strong reactivity within maternal vascular endothelium (Fig. 7) . In the midgestation fetus, greatest bcl-2 expression was present in the telencephalon (Fig. 8) .
Feline Crandall kidney cells. Feline Crandall kidney cells expressed bcl-2 protein diffusely throughout the cytoplasm.
Tumor tissues
Tumors examined included those derived from skin (squamous cell and basal cell carcinoma, carcinoma in situ, ceruminous adenoma, and adenocarcinoma), oral cavity, alimentary tract, nasal cavity, lung, mammary gland, urinary bladder, thyroid gland, lymphoid tissue, fibrous connective tissue (fibrosarcoma), thymus, and meninges. Bcl-2 immunoreactivity of neoplasms is given in Table 2 .
Basal cell tumor. Fourteen feline basal cell tumors were examined, and immunoreactive cells were identified in all tumors. Five tumors showed diffuse, strong cytoplasmic reactivity of 80-100% of tumor cells ( Fig.  9 ), two contained diffusely scattered staining of 40-50% of tumor cells, and four had staining localized to the tumor periphery in 30% of the cells.
Squamous cell carcinoma. Twelve squamous cell carcinomas derived from skin were examined. Ten specimens were sunlight-associated squamous cell carcinomas of the superficial skin of cats with white hair coats, and two tumors were derived from the digit (subungual epithelium). None of the 12 tumors expressed bcl-2. Fewer than 2% of tumor cells in any specimen showed bcl-2 expression, although there was strong reactivity of stromal cells associated with one tumor.
Carcinoma in situ. Eleven in situ carcinomas of the skin were examined; three tumors expressed bcl-2 (30%, 50%, and 100%, respectively).
Ceruminous adenoma and adenocarcinoma. Six ceruminous gland adenomas and six adenocarcinomas were examined; no bcl-2 reactivity was observed in any specimen. . 8 . Midgestation fetus, whole mount sagittal section; cat. There is diffuse immunoreactivity for bcl-2 in the telencephalon (arrow). Avidin-biotin complex/diaminobenzidene-peroxidase, hematoxylin counterstain. Bar ϭ 4 mm. Fig. 9 . Cutaneous basal cell tumor; adult cat. There is diffuse immunoreactivity for bcl-2 in nests of basal epithelial cells. Avidin-biotin complex/diaminobenzidene-peroxidase, hematoxylin counterstain. Bar ϭ 50 m. Fig. 10 . Thyroid adenoma; adult cat. There is immunoreactivity for bcl-2 in neoplastic follicular epithelium. Avidinbiotin complex/diaminobenzidene-peroxidase, hematoxylin counterstain. Bar ϭ 50 m. Fig. 11 . T-cell lymphoma, lymph node; adult cat. Solid sheets of neoplastic lymphocytes show diffuse immunoreactivity for bcl-2. Avidin-biotin complex/diaminobenzidene-peroxidase, hematoxylin counterstain. Bar ϭ 50 m. Oral carcinoma. Ten squamous cell carcinomas derived from gingival mucosae were examined; only one specimen, representing a poorly differentiated squamous cell carcinoma, contained immunoreactive (50%) tumor cells. Scattered lymphocytes associated with tumor stroma expressed bcl-2. Two tonsillar carcinomas were examined, neither of which expressed bcl-2.
Intestinal carcinoma. Fifteen carcinomas derived from the small (n ϭ 8) or large (n ϭ 7) intestine were stained for bcl-2; only one colonic carcinoma contained immunoreactive cells, although in that specimen 90% of tumor cells were strongly reactive. There were no distinguishing features of this tumor as compared with other colonic carcinomas; it was invasive into the wall of the colon and associated with a scirrhous response. For those specimens that contained gut-associated lymphoid tissue, immunoreactive lymphocytes were present in the perifollicular pattern identified above.
Intranasal carcinoma. Six intranasal adenocarcinomas were examined. Two tumors expressed bcl-2; 10% of tumor cells were immunoreactive in an adenocarcinoma with basaloid differentiation, and 70% of tumor cells were immunoreactive in a well-differentiated adenocarcinoma.
Lung carcinoma. Four primary lung carcinomas were examined; one bronchogenic carcinoma expressed bcl-2 (40% of tumor cells).
Urinary bladder carcinoma. Five transitional cell carcinomas of the urinary bladder were studied; none were immunoreactive for bcl-2.
Thyroid adenoma. Twenty thyroid adenomas were examined; 18 expressed bcl-2 ranging from 30% to 100% reactive tumor cells (mean ϭ 69%) ( Fig. 10 ). Associated normal (nonneoplastic) thyroid tissue was present on the histologic section in 9 of 18 bcl-2 expressing tumors. In three adenomas with high bcl-2 expression (80%, 80%, and 85%), there was similar high-level expression in the adjacent nonaffected tissue (100%, 80%, and 90%, respectively), whereas bcl-2 expression was lower in adjacent nonaffected tissue in six specimens as compared with the associated tumors. One thyroid adenoma that had no bcl-2 expression similarly had no expression in the adjacent nonaffected tissue.
Lymphoma. Twenty-one malignant lymphomas, representing a variety of anatomic sites and reflecting both B-and T-cell derivations, were stained for bcl-2 expression. Bcl-2 expression was identified in 11/21 tumors, although there was wide variation in staining patterns ranging from 20% to 100% immunoreactive cells ( Fig. 11 ). Of the immunoreactive tumors, six were derived from T cells and five were derived from B cells. Most nonreactive specimens (8/10) were Bcell-derived tumors, and in general, T-cell-derived tumors had higher bcl-2 expression (mean ϭ 93%) than B-cell-derived tumors (mean ϭ 52%).
Mammary carcinoma. Thirteen of 15 feline mammary carcinomas were immunoreactive for bcl-2 ( Fig.  12 ). Percentage of reactive tumor cells ranged from 20% to 80% (mean ϭ 59%). For two cats, in situ carcinomas were also identified within the specimens examined; both in situ carcinomas expressed bcl-2 (80% and 100% of tumor cells). One nonreactive neoplasm, an apocrine gland carcinoma, had histologic features suggestive of sweat gland rather than mammary gland origin.
Fibrosarcoma. Fourteen fibrosarcomas were examined; one tumor had bcl-2 immunoreactive cells (15%), but all other tumors were negative. Six tumors contained abundant tumor-associated lymphoid cells, of which 80-90% expressed bcl-2.
Meningioma. Eleven meningiomas were examined; only one tumor contained bcl-2 immunoreactive cells (50%).
Thymoma. Eight thymomas were examined; all tumors uniformly expressed bcl-2. In those tumors that maintained lobular architecture, bcl-2 expression was highest (90-100% of cells) within the thymic follicles, whereas 30-70% of cells expressed bcl-2 in the nonfollicular areas. Less well-differentiated thymomas contained 20-50% immunoreactive cells.
Discussion
Bcl-2 expression blocks many instances of apoptotic cell death in a broad range of normal tissues, 12 whereas deregulated bcl-2 extends the survival of certain tumors. 8 The topographic distribution of bcl-2 protein in the adult cats was similar to that described in the human adult; that distribution might be important for determining its normal physiologic role in the cat. In lymphoid tissues, follicular mantle cells strongly expressed bcl-2, but its expression was absent from the proliferating centroblasts. In complex and differentiating epithelium, bcl-2 expression was restricted to stem cell and proliferation zones; it was present in the lower crypts of the intestine. In skin, the basal layer of epidermis showed bcl-2 expression but suprabasilar layers did not. Most thyroid follicular epithelial cells expressed bcl-2. Renal distal convoluted tubules expressed bcl-2, and expression was maintained in the feline kidney cell line.
In feline epithelial tumors, there was strong uniform expression of bcl-2 in all of the cutaneous basal cell tumors examined, but most carcinomas in situ and all squamous cell carcinomas lacked expression. Superficial basal cell tumors in human patients expressed bcl-2 protein 7 but squamous cell carcinomas did not. 4, 21 Basal cell tumors are thought to arise from the basal layer of epidermis, and these findings support that hypothesis. In human basal cell carcinoma, it has been suggested that the tumor is a consequence of bcl-2 expression, leading to suppression of apoptosis and clonal expansion of the basal stem cells rather than increased cellular proliferation. 7 In the human specimens, highest expression of bcl-2 was associated with superficial, indolent, low-grade tumors as compared with more biologically aggressive variants, indicating that bcl-2 expression contributes to nonaggressive growth by blocking apoptotic cell death rather than stimulating cellular division. 7 Feline basal cell tumors are biologically benign, and whether bcl-2 expression correlates with invasion is unknown. The basal cell tumors examined in this study were biologically benign.
Feline lymphomas showed variable expression of bcl-2. Reactivity for bcl-2 protein was greatest toward the periphery of neoplastic follicles, and there was strong reactivity in small lymphocytes in extrafollicular areas. In human tissues, the follicular mantle that contains long-lived recirculating B cells possesses an abundance of bcl-2, and the highest correlation of bcl-2 expression with cancer is in follicular lymphoma, in which approximately 85% of tumors express the protein. 8, 9, 18 Although many of these tumors contain the t(14;18) translocation, both follicular and diffuse lymphomas without rearrangements also show bcl-2 expression, suggesting that mechanisms beyond translocations deregulate bcl-2. 22 Although bcl-2 expression has most often been associated with B-cell-derived tumors in human patients, greater reactivity was detected in this study in feline T-cell-than in B-cell-derived tumors. These findings must not be generalized until a larger group of tumors is examined, but expression of bcl-2 in T-cell-derived tumors suggests a role for that oncoprotein in T-cell salvage. Physiologically, bcl-2 influences T-cell maturation; experiments with transgenic mice demonstrated that bcl-2 expression was present in immature T cells in the cortical thymus. 13 The expression of the bcl-2 protein in feline thymomas is further evidence of the influence of bcl-2 in T-cell maturation and regulation.
Another feline tissue that expressed bcl-2 was the thyroid follicle. In human tissues, glandular epithelium that undergoes hyperplasia in response to hormonal stimuli or growth factors expresses bcl-2. Normal thyroid gland epithelium shows prominent cytoplasmic bcl-2 staining. 8 Similarly, in the cats studied, bcl-2 expression was present in normal (healthy) thyroid follicular epithelium but also in adenomatous hyperplasia or adenomas, which are commonly encountered benign tumors of unknown cause in the thyroid gland of cats that cause clinical signs of hyperthyroidism.
In human tissues, epithelial cells of large and small mammary ducts are reactive for bcl-2. 8 Most feline mammary carcinomas expressed bcl-2. Numerous studies have been done in human breast tumors in an effort to link bcl-2 expression with other prognostic variables and survival times. For example, in one study, expression of bcl-2 genes in human breast cancer was not significantly different from the expression observed in normal breast epithelium, but an imbalance between the expression of antiapoptosis genes and apoptosis-promoting genes was thought to contribute to the pathogenesis of breast cancer. 3 The significance of bcl-2 expression of feline mammary carcinomas remains unknown.
Only one of 11 feline meningiomas examined expressed bcl-2. In one study of human meningiomas, nearly 50% of the tumors expressed bcl-2, as determined using immunohistochemical techniques, although the proteins could be detected in almost all of the tumors by western blot. 16 In another study of human meningioma, bcl-2 expression in those tumors that also had high cellular proliferation was associated with unfavorable prognosis following treatment. 11 Only one of 15 intestinal carcinomas showed bcl-2 expression. In human patients with colonic carcinoma, although bcl-2 is expressed during colonic adenomatous growth, loss of bcl-2 expression is correlated with tumor recurrence and poor prognosis. 10 The family of bcl-2 proteins is critical to the balance between cell survival and cell death, and the results described herein are reflective of only one of those regulatory proteins. The archetypal cell death suppressor protein is bcl-2, whereas cell death inducers facilitate apoptosis. Facilitators of apoptosis include the transcription factor myc, the DNA-repair-associated protein p53, certain cyclin-dependent kinases, and oth-Feline bcl-2 er members of the bcl-2 family, such as bax. 15 Because of the complexity of apoptosis regulation, predicting clinical outcome based on measurement of bcl-2 alone is simplistic; the challenge will be to determine which proteins are the most relevant for predicting responses to treatment or overall survival.
Failure to maintain an appropriate balance of cell numbers is a hallmark of neoplasia. Although increased cellular proliferation is a characteristic feature of some tumors, disruption of apoptosis is also a key event in tumorigenesis. The bcl-2 gene family is considered the prototypic apoptotic regulator. In human patients, defects in the molecular control of apoptosis occur with high frequency in cancer, and different neoplasms often show tumor-specific alterations. 2 Clinically, because apoptosis is induced by most chemotherapeutic and radiotherapeutic agents, bcl-2 expression can cause resistance to therapy. 20 Whether bcl-2 expression confers resistance to therapy in feline tumors was not examined in this study.
Although tumors of diverse histogenesis are encountered frequently in veterinary practice, little is known of the molecular or genetic events associated with tumorigenesis. Feline sarcoma viruses have been productive sources of v-onc genes, rearrangements of c-myc occur in T-cell lymphomas, 6 and preliminary data indicate the presence of p53 mutations or deletions in selected tumors. 17 Bcl-2 is widely expressed in healthy and neoplastic tissues in the cat and probably plays a role in both health and disease.
